Bioray Laboratories is the lead sponsor of 8 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are BRL-301. The most-studied condition is Thalassemia, Beta.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Universal CAR-T Cell Therapy for MM
NCT07248176 · ClinicalTrials.gov ↗ · Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
|
Not applicable | Recruiting | 2025-04 | China |
|
Long-term Follow-up Study of BHC001 for TDT
NCT06314529 · ClinicalTrials.gov ↗ · Thalassemia, Beta
|
Observational | Recruiting | 2022-12 | China |
|
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
NCT05741359 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma,B Cell
|
Phase 1 | Recruiting | 2023-04 | China |
|
Universal CAR-T Cell Therapy for NHL
NCT07248163 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma,B Cell
Drug: BRL-301 |
Not applicable | Recruiting | 2025-03 | China |
|
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630 · ClinicalTrials.gov ↗ · Thalassemia, Beta
|
Observational | Recruiting | 2024-12 | China |
|
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NCT05988216 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
Drug: BRL-301 |
Not applicable | Recruiting | 2023-08 | China |
|
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis
Drug: BRL-301 |
Not applicable | By invitation | 2023-05 | China |
|
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
NCT05577312 · ClinicalTrials.gov ↗ · Beta-Thalassemia
|
Phase 1/2 | Active, closed | 2022-11 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 8 | 6 |
A trial with sites in more than one country appears in each of those registers.
Bioray Laboratories is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are BRL-301 (3). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.